Is It Art or Is It Science? – Scientific American (blog)

At first, it looks like a painting from the school of abstract expressionism. A red, central column spiked with narrow yellow bands stands brilliantly against a black field. But actually this is a photograph capturing bacteria in communication with one another, releasing signal molecules in a process known as quorum sensing. These bacteria have colonized the inside of a flow cell, a chamber that liquid courses through to simulate environments where bacteria live, such as water pipes or your intestines. Minyoung Kevin Kim, a graduate student, photographed this behavior during his research in the Bassler and Stone labs.

His photo, Bacterial Communication in Complex Geometry and Flow, is just one of sixty new works lining the light-filled hallway of Princeton Universitys Friend Center, an engineering library, as part of the eighth Art of Science exhibition. The exhibition showcases images scientists generate during their usual course of research in fields from embryology to plasma physics. These curated images are not merely scientifically relevant; they were chosen for the aesthetic qualities they also possess.

It is scientific data, but it is also art. The exhibitions strength lies in challenging us to hold in our minds these twoseemingly dissonant ideas simultaneously. As an artist and a fourth year doctoral student in chemistry, I love going to the Art of Science. The exhibition subverts the practice of segregating my two passions into mutually exclusive realms, an all too common division I find limiting.

This years exhibition complicates the usual program. I was excited to find, alongside aesthetically pleasing data, artistic works made in the spirit of scientific inquiry, liberally defined. This includes works of art created using scientific materials or pieces exploring scientific concepts in artistic genres, such as dance.

In one such scientifically-infused creative process, a visual arts major, Louisa Willis, experimented with an overhead projector, growing agar plates of bacteria with the projectors heat and imaging the plates with the projectors light. Willis then digitally colored and layered the resulting photographs. Her final product, Bumper Moons (Experiment 8), is eerily beautiful. Colonized dishes now overlap as transparent circles of aqua and ruby. In my own research, I am a frequent streaker of antibiotic selection plates. But Willis, rather than growing bacteria in the conventional way I do, playfully upended this process. By repurposing her projector as incubator and light box both, she created an elegant piece of art/lab equipment.

By including works inspired by science, not strictly products of formal research, the latest exhibition further blurs the traditional boundaries between science and art. Presented as equals, striking juxtapositions emerge. In one video, a ballerina mimics neurotransmission events in the brain, her sharp gestures recalling the opening and closing of gap junctions linking neurons. Looping on another flatscreen is an animation of a subjects fMRI-measured brain activity as they watched the first episode of BBCs Sherlock. I laughed at the absurdity of watching one of my favorite shows in frantic fast forward, perched in the corner of the screen. Looking just below, tiny dots raced around a slowly revolving brain, marking colorful pathways, thought patterns that could have been mine.

Though the images consistently entice, rather than intimidate, the accompanying captions are more inconsistent. Some captions read like obscure scientific abstracts describing a material or technology generally, rather than focusing on the particular image. The best captions explain the content of the image itself and how the image was created.

For example, in Crystalline Mondrian, triangles in shades of blue-gray fracture the frame, creating intriguing alternations of light and dark. Turning to the caption, I discovered that the triangles compose a thin crystal film of rubrene, an organic semiconductor, where each blue is a distinct crystalline domain. Within each domain, rubrene molecules align with each other, but deviate from the alignment of rubrenes gathered in surrounding domains. I was charmed to behold a concrete manifestation of an invisible phenomena: polarized light interacting constructively or destructively with crystalline domains. As the polarized light aligns with or deviates from the angle of each domain, the light reflected is either brighter or dimmer. A fundamental physics principle comes to life in this photograph.

In each piece, viewers glimpse an experts world. An entire field of research hides in a single image or 30 seconds of video. The limited space of each piece heightened my curiosity about the broad, underlying research more effectively than a longwinded lecture or a laboratory visit ever could. The limitations created a pointed strangeness that made me crave a deeper grasp of each subject.

The Art of Science celebrates the visual outputs common to both disciplines. Art and science share a visual language and rely on creative processes. This can be challenging to recognize. Skeptical viewers might dismiss the beauty on display as unintentional, since it is not the primary objective of research. But to dismiss this beauty as accidental is too easy. Here, beauty is not an artifact, but a feature of compelling data.

The exhibition merges art and science at Princeton Universitys Friend Center until January 2018.

Read more here:
Is It Art or Is It Science? - Scientific American (blog)

‘Grey’s Anatomy’ Star Stepping Behind The Scenes In Season 14 – People’s Choice

Johnni Macke 1:00 pm on August 1, 2017

(Photo Courtesy: ABC/Ron Tom)

Starting last month, its been all Greys Anatomy, all the time, due to the fact that season 14 is officially underway (not that were complaining!). Now, weve discovered that one of our favorite Greys actors will not only be on screen this season, but also will be stepping behind the camera.

On Monday (July 31), after spending a few days exploring the beauty that Seattle has to offer and throwing the first pitch at a Seattle Mariners game with his fellow co-stars Kevin McKiddturned his focus to his latest Greys role: directing an episode!

Back at it @greysabc #directorprep, McKidd, who plays Dr. Owen Hunt on the ABC drama captioned a fun selfie of himself, his script, and a BIG cup of coffee.

The Scottish actor has been a part of Greys Anatomy since 2008, when he first won over fans as Cristina Yangs love interest, and since then hes become a fan favorite. In addition to filling out the cast which includes Ellen Pompeo, Justin Chambers, Jesse Williams and more McKidd has been contributing to Greys from behind the scenes since 2011.

Beginning in season 7 of the medical drama, McKidd has directed 16 episodes of Greys Anatomy, and now he is ready to bump that number up to 17 with another directing gig come season 14.

We might not know which episode McKidd is directing yet, but based on showrunner Krista Vernoffs tweet last week, its not episode one, since that story is already wrapped and ready to go.

No matter what episode McKidd is working on, he looks serious in this Instagram post, which we think means hes ready to deliver yet another amazing episode. Plus, he even has a pencil out to take notes with, so you know he means business!

Greys Anatomy returns for season 14 with a two-hour premiere on September 28, 2017 at 8 p.m. on ABC.

See the original post here:
'Grey's Anatomy' Star Stepping Behind The Scenes In Season 14 - People's Choice

Editor’s Note: Anatomy of a political meltdown – Connect Savannah.com

THE CIRCUS-LIKE atmosphere currently dominating the Trump White House seems to be getting some local competition, if last weeks wild and woolly political news at home is any indication.

Savannah politics has a seedy and ugly underbelly. That we already knew.

The ongoing chaos surrounding Alderman Tony Thomas, for example, is just one episode of the long and messy reality TV series we call local politics.

Tensions over the 2018 Congressional midterm elections still a year and a half away! have been running high here since last Februarys town hall meeting with Congressman Buddy Carter.

That event at the Armstrong Center garnered national coverage for the raucous intensity of opposition to the Republican incumbent, who represents Chatham County in Georgias First Congressional District.

But turns out that wild affair was just a prologue.

The latest round of recrimination doesnt involve Buddy Carter so much as it does bizarre internal strife in the Democratic Party ranks.

Or maybe not so much in the actual party ranks after all?

In this issue you will find Jessica Leigh Leboss interview with Lisa Ring, one of the candidates who has announced a bid for the Democratic nomination in order to challenge Carter in November 2018.

As of this writing, Lisa could have one less opponent to worry about.

In the prior issue we ran my interview with another Democratic candidate, Steve Jarvis, whose campaign immediately melted down in ugly fashion even by Savannah standards.

The trouble had already begun before Jarviss official announcement last Thursday (which perhaps symbolically took place during a heavy thunderstorm).

Jarviss admittedly quite conservative positions, as he openly stated in our interview, immediately drew fire from local Democratic activists, who wondered why someone who echoes Donald Trump on some issues would bother running as a Democrat.

Unflattering interactions from campaign staff with people who showed up at the Thursday announcement triggered further hard feelings.

By this past Saturday, things had reached a fever pitch, as internet sleuths discovered that Jarvis had apparently flirted with political runs in his home of Bryan County before, only as a Republican, and seemingly under a slightly different name.

Jarviss former campaign manager Michael Shortt was defending the candidate as late as Saturday afternoon against charges he had run as a Republican.

On Jarviss now-defunct Facebook page, the candidate issued a statement containing the following garbled response:

Several years ago, friends in Bryan County (which is 92% Republican) did try to draft me to run, I declined. If they filled out any forms, its news to me. But even if they did, and if I had, which I didnt, and even if I had been an R instead of a D. So what?

The statement then went on to try and make the case that many folks with Republican leanings citing Hillary Clinton and Elizabeth Warren as examples went on to run as Democrats.

As you might expect, the campaigns response only added fuel to the fire, and made a bad situation that much worse.

Negative comments on Jarviss Facebook page came in fast and furious, with many deleted as fast as they were posted, some with parting shots to the commenters calling them socialists.

By Monday morning the Facebook page was no more.

About an hour later the campaign website itself followed it into oblivion, and was then back up.

By noon Monday, Shortt had officially jumped ship, and he issued this terse statement to the media:

I and my businesses (Tandem, Carbon Media) are no longer representing or affiliated with the Congressional campaign of Steve Jarvis (Bernard Stefan Jarvis) for philosophical and professional reasons.

Meanwhile, I found myself on the receiving end of various personal attacks from a few local political types just for running the Jarvis interview at all though we made it clear that we would be interviewing as many candidates in the race as possible in order to keep things fair.

There seems to be a minor misconception among some that we are only "supposed" to talk to certain types of candidates. (We are endeavoring to interview another candidate for the First District, Adam Bridges, as soon as we can. So get your poison pens ready!)

Savannahs unofficial motto seems to be, No good deed goes unpunished. But we dont apologize for doing our jobs and interviewing people running for office as much and as often as we can.

An interview isnt the same as an endorsement, though apparently some folks dont agree.

The way I see it, our interview was a public service in that it gave readers a chance to see Jarviss policy positions, in his own words, for what they were basically conservative.

Jarvis may have misrepresented a few things, but apparently he was telling the truth about his conservative positions.

Its a free country, and what you do with that information is up to you. Which I guess includes coming up with unhinged conspiracy theories about the hidden evil agenda of the local alt-weekly editor.

All that said, the First District is a very conservative one, and running on a conservative platform is far from the craziest idea if you want to represent it in Congress.

In the meantime, Buddy Carter is planning to hold another town hall meeting, this one on Thursday, Aug. 10, at Bible Baptist School in Savannah.

Except this time, it is a ticketed event. Free to attend, but you have to sign up first.

We are using a ticketing system to ensure constituents of the First District are able to attend town hall meetings in an orderly fashion, says Congressman Carters office.

Will limiting admission make things more orderly?

Or will it invite even more opposition?

Will the next Buddy Carter Town Hall be a circus like the last one?

And will the media be blamed for everything that goes wrong?

Stay tuned for the next episode!

Its must-see stuff, even though some players so far have clearly not been ready for prime time.

cs

See more here:
Editor's Note: Anatomy of a political meltdown - Connect Savannah.com

Anatomy of a Goal: Ola Kamara’s Lefty Finish – Massive Report

Welcome to Anatomy of a Goal, where each week we dissect one goal (or near goal) from the previous weeks Columbus Crew SC match.

For match 23 on the 2017 MLS Season, we take a look at Ola Kamaras 15th minute left-footed goal that put Crew SC up 1-0 as part of the 2-2 draw with Real Salt Lake on Saturday.

Heres a look at the finish from the Columbus forward.

After a disappointing, two red-card loss at the Philadelphia Union on Wednesday night, the Black & Gold found themselves clawing to keep pace in a tight Eastern Conference playoff race. Rookie Connor Maloney earned his first start as a professional, slotting in at right wing back.

Crew SCs opening goal begins off of a clearance by Salt Lake midfielder Kyle Beckerman. Beckermans half-touch only clears the ball about 15 yards up the field.

Captain Wil Trapp and Maloney are both in position to win Beckermans weak clearance. Trapp takes possession of the ball as Maloney heads to a wide position on the right flank.

With a defender on his right hip, Trapp drops the ball back to center-back Nicolai Naess.

Getting his first start since the 1-0 win at Minnesota United, Naess finds himself with the ball and acres yards of space and has four options. He can either carry the ball upfield until defensive pressure arrives, play a long pass to winger Justin Meram, who has begun to move toward Naess, slot a difficult pass to Artur or a pass back to Trapp.

As Meram heads toward Naess, the Crew SC center back plays a beautifully weighted ball to the feet of his teammate.

Meram receives the ball and begins his turn, defended by Beckerman. With a ball-hawking midfielder on his hip, Meram has to quickly decide whether to try and beat Beckerman off the dribble or pass to a teammate.

Meram eludes Beckerman and can either try to beat his defender off the dribble, pass to Maloney on the right wing or slide a quick ball to Artur, potentially setting up a give-and-go.

The Columbus winger takes a nifty dribble away from Beckerman and elects to make an excellent pass across the field to Maloney, who, unmarked, has yards of space to work with.

Danilo Acosta immediately heads over to defend Maloney. Seeing a defender arriving, Artur heads toward his teammate to provide a passing option. Maloney holds onto the ball, waiting for both help to arrive and his defender.

Your browser does not support HTML5 video.

The above video shows the excellent give-and-go that Maloney and Artur execute to get around Acosta and Arturs defender, Sunday Stephen, or Sunny. Maloney plays a short pass to Artur who then plays a ball right between Sunny and Acosta.

Here, Maloney has just made the quick pass. With his defender on his heels, Maloney immediately sets off at a sprint around Acosta. Artur plays the quick pass, setting off a sprint to the ball.

Though Maloney had a bit of a head start, Acosta is able to keep up with the rookie wing back. If Maloney beats Acosta, he will have both Kamara and Ethan Finlay as options for a quick cross.

Maloney JUST beats Acosta to the ball. Meanwhile, Finlay battles for position with Marcelo Silva. Both Silva and Justen Glad are between Finlay and the ball, making it difficult for a pass to reach the Black & Gold winger.

As the ball approaches, Finlay has yet to get into position around Silva. Glad is still in the path of the ball, while Kamara awaits a deflection or rebound.

Glad gets caught on the wrong foot and is unable to get any sort of touch on the cross. Finlay has just gotten a leg in on Silva and attempts a sliding shot on the ball. Kamara is still very open.

Finlays touch on the ball is deflected toward the end line where Maloney is alert and already racing Acosta to the ball. Kamara? Still unmarked.

Maloney gets to the ball, but has to beat Glad if he wants to hit a still wide-open Kamara.

Your browser does not support HTML5 video.

The above video shows Maloneys confident pass through the legs of Glad. Maloney may have gotten lucky, but that lucky pass will become his first professional assist.

From an extra angle you can see Maloneys angle compared to Kamara. Maloney can see that a pass to his teammate would result in a shot on goal. Kamara is mystifyingly still unmarked.

With the ball through Glads legs and headed toward Kamara, the Crew SC striker has an open shot on goal. As Kamara approaches the ball, he decides where to place his shot and with which foot to hit the ball.

A right-footed shot, his natural foot, would be more powerful, but might not have the correct bend. A left-footed shot would be more difficult, but would place the ball in the face of the goal.

Kamara opts for the higher percentage shot with his weak foot. . .

. . . and smashes the ball into the roof of the net.

Your browser does not support HTML5 video.

Findings:

See the rest here:
Anatomy of a Goal: Ola Kamara's Lefty Finish - Massive Report

Cycad leaf physiology research needed – Phys.org – Phys.Org

Healthy juvenile plants of the endangered Cycas micronesica thrive in a deep understory habitat where they effectively utilize infrequent sunflecks. Credit: Thomas Marler

The living cycad species are among the world's most threatened plant groups, but are also among the world's least studied plant groups. The need for a greater understanding of basic physiology of cycads has been discussed for decades, yet to date the needed research is lacking.

Recent reports of how gymnosperms are more sluggish than angiosperms in the photosynthetic use of sunflecks in forest understory settings prompted an article from the University of Guam that appears in the current issue of the journal Plant Signaling & Behavior.

"The list of species used to represent gymnosperms in the conclusions on sunfleck use were restricted to conifers," said author Thomas Marler. "But the world's gymnosperms are also represented by three other groups of plants, and these were not included in the database that was used to formulate conclusions."

The Cycadidae, Ginkgoidae, and Gnetidae groups of plants are also gymnosperms, and collectively they contain close to 400 described species. Guiding principles are needed to improve the representation and relevance of these plants in contemporary research agendas.

According to Marler, the addition of more descriptive research targeting cycad species is welcomed regardless of the approach. But the adherence to protocols that ensure species relevance would improve the outcomes. Since forest canopy traits define sunfleck qualities, the experimental protocols for studying sunfleck use by newly studied species should be defined from the natural habitats of each species. Moreover, the behavior of cultivated plants often differs from that of plants in natural settings, and moving from the current level of minimal knowledge to a level of adequate knowledge may be reached most rapidly by studying these plants within their native range rather than in botanic gardens. A phenomenon called context dependency is also pertinent to the needed expansion of cycad research. Do environmental factors such as drought influence how a cycad plant capitalizes on the ephemeral access to sunflecks?

Attempts to link phylogenetic subsets of plants more closely to the broader global research agenda need to be accurate. Adding more physiology research to cycads would greatly improve our understanding of how the world's plants effectively utilize the pulses of sunlight that punctuate the forest sub-canopy.

Explore further: And one root said to the other root, 'Don't I know you from somewhere?'

More information: Thomas E. Marler, Increasing relevance of sunfleck research, Plant Signaling & Behavior (2017). DOI: 10.1080/15592324.2017.1334030

See the original post here:
Cycad leaf physiology research needed - Phys.org - Phys.Org

IGNOU’s PhD, MPhil admission date extended to Aug 3 – Hindustan Times

New Delhi The Indira Gandhi National Open University (IGNOU) has extended till August 3 the last date of admission for its PhD and MPhil programmes.

IGNOU has invited applications for MPhil in chemistry and geography, PhD in biochemistry, chemistry, French, gender and development studies, geography, geology, journalism and mass communication, fine arts, physics, theatre arts, statistics and womens studies.

IGNOUs research unit director K Barik has said that the last date for PhD and MPhil programmes has been extended till 3 August.

The entrance test for various programmes will be held on August 20 in selected examination centres across the country.

The University, which began academic programmes in 1987, today enrols over three million students in India and other countries through 21 schools of studies and a network of 67 regional centres, around 2,667 learner support centres and 29 overseas partner institutions.

Original post:
IGNOU's PhD, MPhil admission date extended to Aug 3 - Hindustan Times

Seattle Genetics buys biotech factory in Bothell – The Seattle Times

Seattle Genetics has agreed to buy the Bristol-Myers Squibb manufacturing plant in Bothell for $43.3 million, giving the biotech the ability to make its own bulk quantities of antibodies for treating cancer.

Special to The Seattle Times

Seattle Genetics has agreed to buy the Bristol-Myers Squibb manufacturing plant in Bothell for $43.3 million, giving the biotech the ability to make its own bulk quantities of antibodies for treating cancer.

Until now the Bothell-based company has relied entirely on contract manufacturers.

Seattle Genetics will continue to use contract manufacturers because of its international footprint, but this will give us our first manufacturing facility that we actually own, said Clay Siegall, the companys chairman, president and CEO.

About 75 people work at the Bristol-Myers facility on Bothells Monte Villa Parkway. Our hope is to keep the team intact, Siegall said Tuesday.

Seattle Genetics now leases seven buildings in its Canyon Park campus, which is about 20 blocks north of the new property.

The company paid $17.8 million for the land and the building, and an additional $25.5 million for the equipment and the building improvements, Siegall said. The deal gives Seattle Genetics ownership of a fully staffed and operating plant that requires little modification.

Were really excited about this, he said. It gives us the ability to control more of our supply chain.

The company will use the plant to make vials of antibodies that are used to treat cancers. Its leading product, Advetris, is now approved for treating patients with two kinds of lymphomas.

Revenue at Seattle Genetics has climbed steadily in the last five years, but so have the losses. Last year the company lost $140million on total revenue of $418 million, according to company reports.

The sale could set the stage for Bristol-Myers exit from the region.

In December the New York-based company said it would not renew a lease that expires in 2019 for its ZymoGenetics unit on Seattles Lake Union. Bristol-Meyers bought the ZymoGenetics research arm in the former Seattle City Light Steam Plant, as well as the production plant now sold to Seattle Genetics, in 2010 for $885 million.

Originally posted here:
Seattle Genetics buys biotech factory in Bothell - The Seattle Times

Evolutionary biologists identify non-genetic source of species variability – Phys.Org

Pink areas are bone and blue areas are cartilage in this head skeleton of a larval fish. Craig Albertson of UMass Amherst and a colleague report on experiments that looked at how a gaping behavior, a factor in the fish larvae's developmental environment that precedes bone formation, influences later development of cranio-facial bones. Credit: UMass Amherst

An unspoken frustration for evolutionary biologists over the past 100 years, says Craig Albertson at the University of Massachusetts Amherst, is that genetics can only account for a small percentage of variation in the physical traits of organisms. Now he reports experimental results on how another factor, a "bizarre behavior" that is part of early cichlid fish larvae's developmental environment, influences later variation in their craniofacial bones.

Albertson has studied African cichlid fish for 20 years as a model system for exploring how biodiversity originates and is maintained, with a focus on genetic contributions to species differences. In a new series of experiments with former Ph.D. student Yinan Hu, now a postdoctoral fellow at Boston College, they examined a "vigorous gaping" behavior in larval fish that starts immediately after the cartilaginous lower jaw forms and before bone deposition begins. Results appear in the current early online issue of Proceedings of the Royal Society B.

As Albertson explains, "We predicted that the baby fish are exercising their jaw muscles, which should impose forces on the bones they attach to, forces that might stimulate bone formation." Albertson and Hu observed that gaping frequency, which could reach as high as 200 per minute, varied by species "in a way that foreshadows differences in bone deposition around processes critical for the action of jaw opening."

Albertson, an evolutionary geneticist, says, "For over a hundred years, we've been taught that the ability of a system to evolve depends largely on the amount of genetic variation that exists for a trait. What is ignored, or not noted for most traits, is that less than 50 percent of genetic variation can typically be accounted for by genetics." He adds, "Variation in skull shape is highly heritable, so why can we only find genetic variability that accounts for such a small amount of variability in bone development? In my lab we have shifted from elaborating our genetic models to looking more closely at the interaction between genetics and the environment."

How the environment influences development is known as epigenetics in its original and broadest meaning, Albertson points out. Coined in the 1940s to mean anything not encoded in the nucleotide sequence, it has narrowed to refer to how the 3D structure of the DNA molecule is modified, he notes. "That meaning is true, but it isn't the only one. We're returning to the original definition."

In this sense, gaping is part of "a very dynamic developmental environment," Albertson notes. "Bones are not forming in static lumps of tissue. Rather, they are developing as part of, and perhaps in response to, a highly complex and dynamic system." The fact that species differ in gaping rate led the researchers to test the idea that differences in bone development could be accounted for by variation in this behavior. "We performed experiments to see if we could slow the rate in fast-gaping species and speed it up in slow-gaping species, and to see if this behavioral manipulation could influence bone development in predictable ways."

The video will load shortly

Not only did these experiments work, but the magnitude of difference in skeletal morphology induced by these simple shifts in behavior was similar to those predicted to be caused by genetic factors. Albertson says, "What I find really exciting is that in 15 years of manipulating the genetics of craniofacial bone development we can account for up to 20 percent of the variability, so it's modest. When we manipulate gaping behavior, we can influence developmental variability by about 15 percent, which is comparable, almost equal to the genetic response."

The geneticist adds, "When I give talks, this is what surprises colleagues the most, that the environmental effect is on par with the genetic effect, and that it is not systemic but highly specific to important bones involved in fish feeding."

Alberston says this behavior makes sense because "Nature is all about efficiency. Fine-tuning an adaptive response to a particular niche increases the chances of survival. Sometimes longer bones are better, and one way to get there is to kick-start the bone developmental program. This gaping behavior precedes bone formation, so it may represent a way to increase efficiency by setting an animal on the trajectory toward an adaptive phenotype earlier."

He adds, "This is just the beginning. Our field has been entrenched in a gene-centered view of evolution for nearly a century. My hope is that this study adds to a growing body of literature that shows there are other important sources of variation. I hope we can expand the paradigm to consider the environmental context where development takes place, because the effects are likely greater and more widespread than we'd predict."

The next step for his lab will be to figure out how environmental stimuli influence development, Albertson explains. "We now need to understand how bone cells sense and respond to their mechanical environment. What are the molecules that enable this mechano-sensing?"

To this end, the researchers demonstrated that mechanical-load-induced shifts in skeletal development are associated with differences in expression of the ptch1 gene, implicated previously in mediating between-species skeletal shap differences. "That the same molecule is involved in mechano-sensing within species and genetic divergence between species is very cool as it's consistent with evolutionary theory," Albertson says.

The idea is that when an animal population is exposed to a new environment, certain molecules will enable them to respond by conforming their bodies to meet new challenges. If the new environment is stable, natural selection should favor genetic mutations in these molecules that fix the original, transient response. This theory establishes a framework for the initial steps in species divergence. "We think that we now have a molecular foothold into this process," Albertson explains. "These are exciting times."

Explore further: A mechanism of how biodiversity arises

More information: Baby fish working out: An epigenetic source of adaptive variation in the cichlid jaw, Proceedings of the Royal Society B, rspb.royalsocietypublishing.or .1098/rspb.2017.1018

See the original post here:
Evolutionary biologists identify non-genetic source of species variability - Phys.Org

Irvine-based CombiMatrix in $33 million merger deal with Bay Area genetics firm – OCRegister

A medical technologist at CombiMatrix examines live tissue looking for fetal cells to analyze. (File Photo)

From left, medical technologists Lilybeth Wilkens, Meg Purayil, and Catherine Marte work on live samples of tissue at CombiMatrix, a genetic testing lab in Irvine. (File Photo)

Catherine Marte works on live samples of tissue at CombiMatrix, a genetic testing lab in Irvine. (File Photo)

Chief Executive Mark McDonough stands in the lobby of his company, CombiMatrix Corp., in Irvine. The company hopes its testing method will be used to analyze cases of women whove had multiple miscarriages. (File Photo)

Irvine-based CombiMatrix Corp. has agreed to be acquired in an all-stock merger by San Francisco-based Invitae Corp. for $33 million.

The deal between two genetic biotech firms is subject to approval by CombiMatrixs stockholders and regulatory agencies.

CombiMatrix is a molecular diagnostics company that studies theremains of lost pregnancies, extracting DNA that is analyzed to uncover genetic abnormalities that can help explain why the women who gave the samples have had multiple miscarriages. It also does pre-implantation genetic diagnostics and screening, prenatal diagnosis andDNA-based testing forgenetic abnormalities.

In 2014, the companys chief executive, a former Navy navigator, told the Register the companys methods would soon become the standards for analyzing pregnancy loss and prenatal testing.

Merging with Invitae, which also specializes in genetic material and hereditary disorders, should expand the scope of CombiMatrixs reach.

By coming together with Invitae, we believe we can synergistically combine their scale, technology and expertise with the CombiMatrix product offering, human capital and sales channels to achieve even greater success in the future for the company and our shareholders, Mark McDonough, president and chief executive officer of CombiMatrix, said in a statement.

CombiMatrix will be a wholly-owned subsidiary of Invitae, according to documents filed with the Securities and Exchange Commission.

The company declined to provide any information not found in SEC documents, such as potential job impacts or executive changes.

For many people, preparing to have a child is their introduction to the power of genetics to inform health decisions, Sean George, chief executive officer of Invitae, said in a statement. The combination of Invitae and CombiMatrix will expand our ability to provide actionable answers to the complex questions that can arise when starting a family.

Testing has become more common as women have babies later in life. In 2016, theaverage age when women have their first child was 28. In 1970, it was 24.6, according to the CDC.

McDonough, in 2014, said he saw a market of up to $200 million a year for so called microarray prenatal testing and a$330 million marketfor recurrent pregnancy loss.

CombiMatrixspun off of Newport Beach-basedAcacia Research Corp. in 2007. It got its start supplyinglaboratories conducting microarray tests with biotech tools before founding a genetic testing lab.

In 2010, it moved to Irvine from Seattle.

Invitaeon Monday said it is also acquiring Cambridge, Mass.-based Good Start Genetics, another pregnancy-related molecular diagnostics company that specializes in preimplantation and carrier screening.

Read the rest here:
Irvine-based CombiMatrix in $33 million merger deal with Bay Area genetics firm - OCRegister

Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing … – Motley Fool

Seattle Genetics (NASDAQ:SGEN) reported second-quarter revenue and earnings numbers, but the conference call focused mostly on potential near-term revenue growth for the biotech's one approved drug, Adcetris, with one expanded indication under review at the FDA and another to be there shortly.

Metric

Q2 2017

Q2 2016

Year-Over-Year Change

Revenue

$108.2 million

$95.4 million

13.4%

Income from operations

($59.4 million)

($33.4 million)

N/A

Earnings per share

($0.39)

($0.23)

N/A

Data source: Seattle Genetics.

Image source: Getty Images.

"Based on our review of pooled, blinded PFS events in the E2 trial, we have observed a lower rate of progression events compared with our projections. We plan to interact with FDA about the potential to unblind the trial prior to reaching the prespecified number of events. Based on the length of patient follow-up, we believe the trial data will be mature in 2018 and continue to expect to report E2 data next year." -- Seattle Genetics CEO and chairman Clay Siegall

There are a lot of terms in that quote, so let's break them down:

Blinded: The company doesn't know which drug the patients in the trial were treated with.

PFS: Progression-free survival, a measure of efficacy based on how long it takes a patient to progress or die -- whichever comes first -- while being treated.

E2: ECHELON-2, a clinical trial testing Adcetris in patients with mature T-cell lymphoma who haven't been previously been treated.

So to translate: Patients aren't progressing or dying as fast as expected, which is good news for patients and hopefully good news for Seattle Genetics if it's the patients being treated with Adcetris who are the ones responding better than expected, but we don't know for sure since the company is blinded. Since the trial is set up to end when a certain number of progression/deaths occur in both treatment arms combined, the trial is taking longer to complete than expected, so management plans to ask the FDA for permission to look at the data earlier.

Management increased 2017 guidance for ADCETRIS sales in the U.S. and Canada to a range of $290million to$310million. Not bad, but far from a blockbuster, which will only come from successful approval based on the ECHELON-1 trial. Investors will get a full look at that data at the American Society of Hematology meeting in December.

Beyond the aforementioned plan to get ECHELON-2 data earlier, Seattle Genetics has other clinical trial data coming. It recently started a phase 3 trial with Bristol-Myers Squibb testing Adcetris plus Bristol's Opdivo in relapsed or refractory Hodgkin lymphoma patients. And enfortumab vedotin, which is partnered with Astellas, will enter a phase 2 trial in metastatic urothelial cancer that management thinks should be enough to gain accelerated approval from the FDA if the trial is successful.

The rest is here:
Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing ... - Motley Fool